• Published On : Sep-2018 |
  • Pages : 274 Pages |
  • Format :

1. Executive Summary
     1.1. Market Overview
     1.2. Market Analysis
     1.3. PMR Analysis and Recommendations
     1.4. Wheel of Fortune

2. Market Introduction
     2.1. Market Definition
     2.2. Market Taxonomy

3. Anti-Cancer Drugs Market Opportunity Analysis
     3.1. Macro-Economic Factors
     3.2. Opportunity Analysis

4. Market Background
     4.1. Recent Developments
     4.2. Market Dynamics
            4.2.1. Drivers
            4.2.2. Restraints
            4.2.3. Trends
     4.3. Reimbursement Landscape
     4.4. Regulatory Scenario

5. Macroeconomic Assumptions

6. Global Economic Outlook
     6.1. Gross Domestic Product by Region & Country, 2006 – 2021
     6.2. Disease Outlook

7. Key Inclusions
     7.1. Epidemiology
     7.2. Pipeline Analysis
     7.3. Mergers and Acquisitions

8. North America Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
     8.1. Introduction
     8.2. Historical Market Value (US$ Mn) Analysis By Country, 2012–2016
            8.2.1. U.S.
            8.2.2. Canada
     8.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
     8.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
            8.4.1. Cytotoxics
            8.4.2. Hormonal Therapy
            8.4.3. Targeted Therapy
                     8.4.3.1. Monoclonal antibodies
                     8.4.3.2. Small molecule inhibitors
     8.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
     8.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
            8.6.1. Prostate Cancer
            8.6.2. Lung Cancer
            8.6.3. Breast Cancer
            8.6.4. Melanoma
            8.6.5. Leukemia
            8.6.6. Others
     8.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
     8.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
            8.8.1. Hospital Pharmacies
            8.8.2. Retail Pharmacies
     8.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
     8.10. Market Attractiveness Analysis
            8.10.1. By Country
            8.10.2. By Drug Class
            8.10.3. By Indications
            8.10.4. By Distribution Channels
     8.11. Key Market Participants – Intensity Mapping
     8.12. Drivers and Restraints – Impact Analysis

9. Latin America Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
     9.1. Introduction
     9.2. Historical Market Value (US$ Mn) Trends Analysis By Country, 2012–2016
            9.2.1. Brazil
            9.2.2. Mexico
            9.2.3. Rest of Latin America
     9.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
     9.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
            9.4.1. Cytotoxics
            9.4.2. Hormonal Therapy
            9.4.3. Targeted Therapy
                     9.4.3.1. Monoclonal antibodies
                     9.4.3.2. Small molecule inhibitors
     9.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
     9.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
            9.6.1. Prostate Cancer
            9.6.2. Lung Cancer
            9.6.3. Breast Cancer
            9.6.4. Melanoma
            9.6.5. Leukemia
            9.6.6. Others
     9.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
     9.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
            9.8.1. Hospital Pharmacies
            9.8.2. Retail Pharmacies
     9.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
     9.10. Market Attractiveness Analysis
            9.10.1. By Country
            9.10.2. By Drug Class
            9.10.3. By Indications
            9.10.4. By Distribution Channels
     9.11. Key Market Participants – Intensity Mapping
     9.12. Drivers and Restraints – Impact Analysis

10. Europe Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
     10.1. Introduction
     10.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016
            10.2.1. Germany
            10.2.2. U.K.
            10.2.3. France
            10.2.4. Italy
            10.2.5. Spain
            10.2.6. Russia
            10.2.7. Rest of Europe
     10.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
     10.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
            10.4.1. Cytotoxics
            10.4.2. Hormonal Therapy
            10.4.3. Targeted Therapy
                     10.4.3.1. Monoclonal antibodies
                     10.4.3.2. Small molecule inhibitors
     10.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
     10.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
            10.6.1. Prostate Cancer
            10.6.2. Lung Cancer
            10.6.3. Breast Cancer
            10.6.4. Melanoma
            10.6.5. Leukemia
            10.6.6. Others
     10.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
     10.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
            10.8.1. Hospital Pharmacies
            10.8.2. Retail Pharmacies
     10.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
     10.10. Market Attractiveness Analysis
            10.10.1. By Country
            10.10.2. By Drug Class
            10.10.3. By Indications
            10.10.4. By Distribution Channels
     10.11. Key Market Participants – Intensity Mapping
     10.12. Drivers and Restraints – Impact Analysis

11. Asia Pacific Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
     11.1. Introduction
     11.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016
            11.2.1. China
            11.2.2. India
            11.2.3. Australia and NZ
            11.2.4. ASEAN
            11.2.5. Rest of Asia Pacific
     11.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
     11.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
            11.4.1. Cytotoxics
            11.4.2. Hormonal Therapy
            11.4.3. Targeted Therapy
                     11.4.3.1. Monoclonal antibodies
                     11.4.3.2. Small molecule inhibitors
     11.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
     11.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
            11.6.1. Prostate Cancer
            11.6.2. Lung Cancer
            11.6.3. Breast Cancer
            11.6.4. Melanoma
            11.6.5. Leukemia
            11.6.6. Others
     11.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
     11.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
            11.8.1. Hospital Pharmacies
            11.8.2. Retail Pharmacies
     11.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
     11.10. Market Attractiveness Analysis
            11.10.1. By Country
            11.10.2. By Drug Class
            11.10.3. By Indications
            11.10.4. By Distribution Channels
     11.11. Key Market Participants – Intensity Mapping
     11.12. Drivers and Restraints – Impact Analysis

12. Japan Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
     12.1. Introduction
     12.2. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
            12.2.1. Cytotoxics
            12.2.2. Hormonal Therapy
            12.2.3. Targeted Therapy
                     12.2.3.1. Monoclonal antibodies
                     12.2.3.2. Small molecule inhibitors
     12.3. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
     12.4. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
            12.4.1. Prostate Cancer
            12.4.2. Lung Cancer
            12.4.3. Breast Cancer
            12.4.4. Melanoma
            12.4.5. Leukemia
            12.4.6. Others
     12.5. Market Value (US$ Mn) Forecast By Indications, 2017–2025
     12.6. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
            12.6.1. Hospital Pharmacies
            12.6.2. Retail Pharmacies
     12.7. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
     12.8. Market Attractiveness Analysis
            12.8.1. By Drug Class
            12.8.2. By Indications
            12.8.3. By Distribution Channels
     12.9. Key Market Participants – Intensity Mapping
     12.10. Drivers and Restraints – Impact Analysis

13. Middle East & Africa Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
     13.1. Introduction
     13.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016
            13.2.1. South Africa
            13.2.2. GCC Countries
            13.2.3. Rest of MEA
     13.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
     13.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
            13.4.1. Cytotoxics
            13.4.2. Hormonal Therapy
            13.4.3. Targeted Therapy
                     13.4.3.1. Monoclonal antibodies
                     13.4.3.2. Small molecule inhibitors
     13.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
     13.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
            13.6.1. Prostate Cancer
            13.6.2. Lung Cancer
            13.6.3. Breast Cancer
            13.6.4. Melanoma
            13.6.5. Leukemia
            13.6.6. Others
     13.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
     13.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
            13.8.1. Hospital Pharmacies
            13.8.2. Retail Pharmacies
     13.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
     13.10. Market Attractiveness Analysis
            13.10.1. By Country
            13.10.2. By Drug Class
            13.10.3. By Indications
            13.10.4. By Distribution Channels
     13.11. Key Market Participants – Intensity Mapping
     13.12. Drivers and Restraints – Impact Analysis

14. Forecast Factors: Relevance and Impact

15. Forecast Assumptions

16. Competition Analysis
     16.1. Competition Dashboard
     16.2. Company Deep Dive
            16.2.1. F. Hoffmann-La Roche Ltd
                     16.2.1.1. Overview
                     16.2.1.2. Product  and Indications Portfolio
                     16.2.1.3. Production Footprint
                     16.2.1.4. Sales Footprint
                     16.2.1.5. Channel Footprint
                     16.2.1.6. Strategy
                                16.2.1.6.1.1. Marketing Strategy
                                16.2.1.6.1.2. Product Strategy
                                16.2.1.6.1.3. Channel Strategy
            16.2.2. Celgene Corp
                     16.2.2.1. Overview
                     16.2.2.2. Product  and Indications Portfolio
                     16.2.2.3. Production Footprint
                     16.2.2.4. Sales Footprint
                     16.2.2.5. Channel Footprint
                     16.2.2.6. Strategy
                                16.2.2.6.1.1. Marketing Strategy
                                16.2.2.6.1.2. Product Strategy
                                16.2.2.6.1.3. Channel Strategy
            16.2.3. Novartis AG
                     16.2.3.1. Overview
                     16.2.3.2. Product  and Indications Portfolio
                     16.2.3.3. Production Footprint
                     16.2.3.4. Sales Footprint
                     16.2.3.5. Channel Footprint
                     16.2.3.6. Strategy
                                16.2.3.6.1.1. Marketing Strategy
                                16.2.3.6.1.2. Product Strategy
                                16.2.3.6.1.3. Channel Strategy
            16.2.4. Bristol-Myers Squibb Co
                     16.2.4.1. Overview
                     16.2.4.2. Product  and Indications Portfolio
                     16.2.4.3. Production Footprint
                     16.2.4.4. Sales Footprint
                     16.2.4.5. Channel Footprint
                     16.2.4.6. Strategy
                                16.2.4.6.1.1. Marketing Strategy
                                16.2.4.6.1.2. Product Strategy
                                16.2.4.6.1.3. Channel Strategy
            16.2.5. Johnson & Johnson
                     16.2.5.1. Overview
                     16.2.5.2. Product  and Indications Portfolio
                     16.2.5.3. Production Footprint
                     16.2.5.4. Sales Footprint
                     16.2.5.5. Channel Footprint
                     16.2.5.6. Strategy
                                16.2.5.6.1.1. Marketing Strategy
                                16.2.5.6.1.2. Product Strategy
                                16.2.5.6.1.3. Channel Strategy
            16.2.6. Merck & Co.
                     16.2.6.1. Overview
                     16.2.6.2. Product  and Indications Portfolio
                     16.2.6.3. Production Footprint
                     16.2.6.4. Sales Footprint
                     16.2.6.5. Channel Footprint
                     16.2.6.6. Strategy
                                16.2.6.6.1.1. Marketing Strategy
                                16.2.6.6.1.2. Product Strategy
                                16.2.6.6.1.3. Channel Strategy
            16.2.7. Eli Lilly and Company
                     16.2.7.1. Overview
                     16.2.7.2. Product  and Indications Portfolio
                     16.2.7.3. Production Footprint
                     16.2.7.4. Sales Footprint
                     16.2.7.5. Channel Footprint
                     16.2.7.6. Strategy
                                16.2.7.6.1.1. Marketing Strategy
                                16.2.7.6.1.2. Product Strategy
                                16.2.7.6.1.3. Channel Strategy
            16.2.8. AstraZeneca plc
                     16.2.8.1. Overview
                     16.2.8.2. Product  and Indications Portfolio
                     16.2.8.3. Production Footprint
                     16.2.8.4. Sales Footprint
                     16.2.8.5. Channel Footprint
                     16.2.8.6. Strategy
                                16.2.8.6.1.1. Marketing Strategy
                                16.2.8.6.1.2. Product Strategy
                                16.2.8.6.1.3. Channel Strategy
            16.2.9. Amgen Inc..
                     16.2.9.1. Overview
                     16.2.9.2. Product  and Indications Portfolio
                     16.2.9.3. Production Footprint
                     16.2.9.4. Sales Footprint
                     16.2.9.5. Channel Footprint
                     16.2.9.6. Strategy
                                16.2.9.6.1.1. Marketing Strategy
                                16.2.9.6.1.2. Product Strategy
                                16.2.9.6.1.3. Channel Strategy
            16.2.10. Roche Holding AG
                     16.2.10.1. Overview
                     16.2.10.2. Product  and Indications Portfolio
                     16.2.10.3. Production Footprint
                     16.2.10.4. Sales Footprint
                     16.2.10.5. Channel Footprint
                     16.2.10.6. Strategy
                                16.2.10.6.1.1. Marketing Strategy
                                16.2.10.6.1.2. Product Strategy
                                16.2.10.6.1.3. Channel Strategy

17. Global Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Region
     17.1. Introduction/Key Findings
     17.2. Historical Market Value (US$ Mn) Trend Analysis By Region, 2012–2016
     17.3. Market Value (US$ Mn) Forecast By Region, 2017–2025
            17.3.1. North America
            17.3.2. Latin America
            17.3.3. Europe
            17.3.4. Asia Pacific
            17.3.5. Middle East & Africa
            17.3.6. China
     17.4. Market Attractiveness Analysis By Region

18. Global Anti-Cancer Drugs Analysis 2012–2016 and Forecast 2017–2025, By Drug Class
     18.1. Introduction/Key Findings
     18.2. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
            18.2.1. Cytotoxics
            18.2.2. Hormonal Therapy
            18.2.3. Targeted Therapy
                     18.2.3.1. Monoclonal antibodies
                     18.2.3.2. Small molecule inhibitors
     18.3. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
     18.4. Market Attractiveness Analysis

19. Global Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Indications
     19.1. Introduction/Key Findings
     19.2. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
            19.2.1. Prostate Cancer
            19.2.2. Lung Cancer
            19.2.3. Breast Cancer
            19.2.4. Melanoma
            19.2.5. Leukemia
            19.2.6. Others
     19.3. Market Value (US$ Mn) Forecast By Indications, 2017–2025
     19.4. Market Attractiveness Analysis By Indications

20. Global Anti-cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Distribution Channels
     20.1. Introduction/Key Findings
     20.2. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
            20.2.1. Hospital Pharmacies
            20.2.2. Retail Pharmacies
     20.3. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
     20.4. Market Attractiveness Analysis By Distribution Channels

21. Global Anti-Cancer Drugs  Market Analysis 2012–2016 and Forecast 2017–2025
     21.1. Market Value Share Analysis By All Segment
     21.2. Y-o-Y Growth Analysis By All Segment
     21.3. Absolute $ Opportunity

22. Research Methodology


List of Tables

Table 01A: Funding by Research Areas 2017 (US $Millions)
Table 01A: Funding by Research Areas 2017 (US $Millions)
Table 01B: Funding by Research Areas 2017 (US $Millions)
Table 02A: New Active Substances Launched in 2017 and Summary of Clinical Benefits
Table 02B: New Active Substances Launched in 2017 and Summary of Clinical Benefits
Table 02C: New Active Substances Launched in 2017 and Summary of Clinical Benefits
Table 03: Estimated Number of Deaths for the Four Major Cancers by Sex and Age Group, 2017
Table 04: Estimated New Cases for the Four Major Cancers by Sex and Age Group, 2016
Table 05: Difference in approval times between EMEA and FDA for selected targeted therapies
Table 06: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 07: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 8A: Prevalence of Cancer in North America, 2017
Table 8B: Prevalence of Cancer in Latin America, 2017
Table 8C: Prevalence of Cancer in Asia Pacific, 2017
Table 8D: Prevalence of Cancer in Europe, 2017
Table 09: Number of FDA Approvals (2010-2017)
Table 10: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 11: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 12: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 13: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 14: North America Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 15: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 16: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 17: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 18: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 19: North America Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 20: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 21: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 22: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 23: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 24: Europe Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 25: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 26: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 27: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 28: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 29: Asia Pacific Excluding Japan Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 30: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 31: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 32: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 33: Japan Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 34: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 35: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 36: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 37: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 38: Middle East and Africa Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 39A: Competition Dashboard
Table 39B: Competition Dashboard
Table 39C: Competition Dashboard
Table 40: Anticancer Drugs Market Value (US$ Mn) 2013–2017 and Forecast 2018-2026 By Region
Table 41: Global Anticancer Drugs Market Value Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 42: Global Anticancer Drugs Market Value Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indications
Table 43: Global Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channels


List of Figures

Figure 01: Global Anticancer Drugs Market Value Share By Drug Class (2018 E)
Figure 02: Global Anticancer Drugs Market Value Share By Indications (2018 E)
Figure 03: Global Anticancer Drugs Market Value Share By Distribution Channel (2018 E)
Figure 04: Global Anticancer Drugs Market Value Share By Regions (2018 E)
Figure 05: New Cancer Drugs Approved Each Year
Figure 06 : Growth of the Late Phase Oncology Pipeline, 2005-2015
Figure 07: The Global Late Phase Oncology Pipeline in 2015
Figure 08: Estimates Of National Expenditures For Cancer Care (In Billions Of Dollars) By Cancer Site And Year
Figure 09: Availability of 55 Oncology Medicines First Launched Globally 2012—2016
Figure 10: Number of FDA approved pharmaceuticals (2010-2017)
Figure 11 : North America Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 12 : North America Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 13 : Canada Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 14 : U.S. Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 15 : Canada Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 16 : U.S. Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 17 : Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 18 : Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 19 : Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 20 : Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 21 : Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 22: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 23: North America Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 24: North America Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026 (US$ Mn)
Figure 25: North America Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 26: North America Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 27: Latin Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 28: Latin Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 29: Mexico Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 30: Brazil Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 31: Mexico Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 32: Brazil Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 33: Rest of Latin America Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 34: Rest of Latin America Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 35: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 36: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 37: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 38: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 39: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 40: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 41: Latin America Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 42: Latin America Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
Figure 43: Latin America Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 44: Latin America Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 45: Europe Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 46: Europe Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 47: Germany Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 48: U.K. Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 49: Germany Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 50: U.K. Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 51: Italy Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 52: France Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 53: Italy Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 54: France Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 55: Russia Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 56: Spain Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 57: Russia Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 58: Spain Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 59: Rest of Europe Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 60: Rest of Europe Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 61: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 62: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 63: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 64: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 65: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 66: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 67: Europe Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 68: Europe Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
Figure 69: Europe Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 70: Europe Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 71: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 72: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 73: India Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 74: China Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 75: India Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 76: China Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 77: ASEAN Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 78: Australia and NZ Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 79: ASEAN Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 80: Australia and NZ Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 81: Rest of Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 82: Rest of Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 83: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 84: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 85: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 86: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 87: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 88: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 89: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 90: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
Figure 91: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 92: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 93: Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 94: Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 95: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 96: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 97: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 98: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 99: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 100: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 101: Japan Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 102: Japan Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026 (US$ Mn)
Figure 103: Japan Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 104: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 105: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 106: GCC Countries Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 107: South Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 108: GCC Countries Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 109: South Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 110: Rest of Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 111: Rest of Middle East and Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 112: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 113: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 114: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 115: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 116: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 117: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 118: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 119: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
Figure 120: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 121: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 122: Revenue Contribution by Tier Type
Figure 123: Global Anticancer Drugs Market Structure
Figure 124: Global Anticancer Drugs Market Share Analysis (%) By Region, 2018 & 2026
Figure 125: Global Anticancer Drugs Market Y-o-Y Growth (%) By Region, 2017–2026
Figure 126: Global Anticancer Drugs Market Attractiveness Analysis By Region, 2018–2026
Figure 127: Global Anticancer Drugs Market Share
Figure 128: Anticancer Drugs Market Y-o-Y Growth (%) By Drug Class, 2017–2026
Figure 129: Global Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018–2026
Figure 130: Global Anticancer Drugs Market Share
Figure 131: Anticancer Drugs Market Y-o-Y Growth (%) By Indications, 2017–2026
Figure 132: Global Anticancer Drugs Market Attractiveness Analysis By Indications, 2018–2026
Figure 133: Global Anticancer Drugs Market Share Analysis (%) By Distribution Channels, 2018 & 2026
Figure 134: Global Anticancer Drugs Market
Figure 135: Global Anticancer Drugs Market Attractiveness Analysis By Distribution Channels, 2018–2026
Figure 136: Global Anticancer Drugs Market Value Analysis and Forecast, 2017–2026 (US$ Mn)
Figure 137: Global Anticancer Drugs Market Absolute $ Opportunity (US$ Mn), 2017–2026